NBDC Research ID: hum0320.v1

 

SUMMARY

Aims: Various immunocompetent cells and factors in the peripheral blood cells and tumor tissues of patients with malignant tumors were analyzed. The immunological status of patients with malignant tumors will be clarified by analyzing various immune cells and factors in peripheral blood cells and tumor tissues. The relationship between immune status and clinicopathological characteristics, molecular biological characteristics, therapeutic effects, and prognosis will be evaluated as well.

Methods: Expressions of CD4, CD8, FoxP3, CD25, CD45RA, CTLA-4, PD-1, ICOS, BTLA, Tim-3, LAG3, CCR7, and other molecules on immunocompetent cells (CD4/CD8 T cells, antigen-presenting cells, regulatory T cells, MDSCs, spontaneous lymphocytes, etc.) were analyzed by single-cell sequencing technology. The T-cell receptor (TCR) of immune cells was also analyzed in the same technology.

Participants/Materials: pulmonary gland cancer: 2 cases, head and neck part cancer: 3 cases

 

Dataset IDType of DataCriteriaRelease Date
JGAS000480 NGS (scRNA-seq, TCR-seq) Controlled-access (Type I) 2022/01/25

*Release Note

*Data users need to apply an application for Using NBDC Human Data to reach the Controlled-access Data. Learn more

 

MOLECULAR DATA

scRNA-seq

Participants/Materials

lung adenocarcinoma (ICD10: C349): 2 cases

head and neck cancer (ICD10: C760): 3 cases

    tumor tissue: 1 sample each

    lymph node: 1 sample each

    peripheral blood; 1 sample each

     (Total 15 samples)

Targets scRNA-seq
Target Loci for Capture Methods -
Platform MGI [DNBSEQ-G400]
Library Source RNAs extracted from a single T cell isolated from tumor tissues, lymph node,s and peripheral blood cells
Cell Lines -
Library Construction (kit name) Chromium Next GEM Single Cell 5' Reagent Kits v2
Fragmentation Methods Hybrid Selection
Spot Type Paired-end
Read Length (without Barcodes, Adaptors, Primers, and Linkers) average 100 bp
Japanese Genotype-phenotype Archive Dataset ID JGAD000597
Total Data Volume 719.9 GB (fastq)
Comments (Policies) NBDC policy

 

TCR-seq

Participants/Materials

lung adenocarcinoma (ICD10: C349): 2 cases

head and neck cancer (ICD10: C760): 3 cases

    tumor tissue: 1 sample, lymph node: 1 sample, peripheral blood; 1 sample, Total 15 samples

Targets TCR-seq
Target Loci for Capture Methods -
Platform MGI [DNBSEQ-G400]
Library Source RNAs extracted from a single T cell isolated from tumor tissue, lymph node and peripheral blood
Cell Lines -
Library Construction (kit name) Chromium Next GEM Single Cell 5' Reagent Kits v2
Fragmentation Methods Hybrid Selection
Spot Type Paired-end
Read Length (without Barcodes, Adaptors, Primers, and Linkers) average 100 bp
Japanese Genotype-phenotype Archive Dataset ID JGAD000597
Total Data Volume 719.9 GB (fastq)
Comments (Policies) NBDC policy

 

DATA PROVIDER

Principal Investigator: Yosuke Togashi

Affiliation: Chiba Cancer Center Research Institute

Project / Group Name: -

Funds / Grants (Research Project Number):

NameTitleProject Number
KAKENHI Grant-in-Aid for Scientific Research (B) Analysis of PD-1+ tumor-infiltrating T cells according to cancer antigen hierarchy 20H03694
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED) Spatial and temporal analysis of neoantigen-specific T-cell clones as a therapeutic target and biomarker JP19ck0106521
Project for Cancer Research and Therapeutic Evolution (P-CREATE), Japan Agency for Medical Research and Development (AMED) Novel tumor-infiltrating T cell analysis according to antigen epitope JP18cm0106340

 

PUBLICATIONS

TitleDOIDataset ID
1 PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes doi: 10.1016/j.celrep.2022.110331 JGAD000597
2

 

USRES (Controlled-access Data)

Principal InvestigatorAffiliationCountry/RegionResearch TitleData in Use (Dataset ID)Period of Data Use
Ansuman Satpathy Department of Pathology, Stanford University United States of America Epigenetics of Inflammatory Skin Disorders JGAD000597 2022/07/04-2023/05/31